Loading grant details…
E!167, APTAMER, Icellate Medical AB
| Funder | Vinnova |
|---|---|
| Recipient Organization | Icellate Medical Ab |
| Country | Sweden |
| Start Date | Jun 01, 2022 |
| End Date | May 31, 2024 |
| Duration | 730 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | Swedish Research Council |
| Grant ID | 2022-00811_Vinnova |
Grant Description
Purpose and goal:
iCellate has completed development of a new blood-based companion diagnostic test, CellMate® Ewing sarcoma, for the new Ewing sarcoma drug ADEL-101.
The new test aims to non-invasively predict treatment safety and efficacy of the ADEL-101 drug for the individual patient by taking samples of individual cancer cells. Expected results and effects:
We judge that the CellMate® Ewing Sarcoma test is ready to be matched against ADEL-101 treatment safety and efficacy in a phase 2 study. Approach and implementation:
The APTAMER project is a near-ideal opportunity to demonstrate the universality and flexibility of the CellMate® oncological in vitro companion diagnostic platform technology for new targeted oncology therapies.
All Grantees
Icellate Medical Ab
Interested in applying for this grant?
Complete our application form to express your interest and we'll guide you through the process.
Apply for This GrantQuick Summary
Related Grants
